

*I1  
encl*

least one polypeptide from the early region of a human papillomavirus and at least one polypeptide from the late region of a human papillomavirus with the exception of the specific combination of a polypeptide from the E7 early region of a human papillomavirus and a polypeptide from the L2 late region of a human papillomavirus and wherein said polypeptide from the early region of a human papillomavirus and said polypeptide from the late region of a human papillomavirus are expressed recombinantly from independent expression control elements.

*I2*

40. (Amended) The pharmaceutical composition according to claim 38, wherein the polypeptide from the early region of a papillomavirus is a nononcogenic variant of the E6 and/or E7 protein of a papillomavirus.

*I3*

47. (Amended) A pharmaceutical composition intended for the treatment or prevention of a papillomavirus infection or tumor, which comprises as therapeutic agents at least one polypeptide from the early region of a papillomavirus and at least one polypeptide from the late region of a papillomavirus and at least one polypeptide having an immunostimulatory activity, wherein said polypeptide from the early region of a papillomavirus and said polypeptide from the late region of a papillomavirus and said polypeptide having an immunostimulatory activity are expressed recombinantly from independent expression control elements and wherein said polypeptide having

*I<sup>3</sup>*  
*incld*  
immunostimulatory activity is selected from the group consisting of interleukin-2, interleukin-7, the co-adhesion molecule B7.1 and the co-adhesion molecule B7.2.

---

*I<sup>4</sup>*  
49. (Amended) The pharmaceutical composition according to claim 47, wherein the polypeptide from the early region of a papillomavirus is a nononcogenic variant of the E6 and/or E7 protein of a papillomavirus.

---

*I<sup>5</sup>*  
52. (Amended) The pharmaceutical composition according to claim 47, wherein the polypeptide having an immunostimulatory activity is interleukin-2.

---

53. (Amended) The pharmaceutical composition according to claim 47, wherein the polypeptide having an immunostimulatory activity is the co-adhesion molecule B7.1.

---

*I<sup>6</sup>*  
55. (Amended) The pharmaceutical composition of claim 47, wherein said composition comprises:

- (a) a nononcogenic variant of an E6 protein of a human papillomavirus, wherein said nononcogenic variant is a variant of the native E6 protein having amino acids 111-115 deleted as compared to the native E6 protein,
- (b) a nononcogenic variant of an E7 protein of a human papillomavirus, wherein said nononcogenic variant is a variant of the native E7 protein having amino acids 21-26 deleted as compared to the native E7 protein,

- I<sup>b</sup>  
concl<sup>d</sup>*
- (c) a polypeptide from the L1 region of a human papillomavirus,
  - (d) a polypeptide from the L2 region of a human papillomavirus, and
  - (e) interleukin-2.

*I<sup>7</sup>*

63. (Amended) A pharmaceutical composition intended for the treatment or prevention of a papillomavirus infection or tumor, which comprises as therapeutic agents at least one polypeptide from the early region or late region of a papillomavirus and at least one polypeptide having an immunostimulatory activity, wherein said polypeptide from the early region of a papillomavirus and said polypeptide from the late region of a papillomavirus and said polypeptide having an immunostimulatory activity are expressed recombinantly from independent expression control elements and wherein said polypeptide having an immunostimulatory activity is selected from the group consisting of interleukin-1, interleukin-7, the co-adhesion molecule B7.1 and the co-adhesion molecule B7.2.

*I<sup>8</sup>*

65. (Amended) The pharmaceutical composition according to claim 63, wherein the polypeptide from the early region of a papillomavirus is a nononcogenic variant of the E6 and/or E7 protein of a papillomavirus.

*I<sup>9</sup>*

68. (Amended) The pharmaceutical composition according to claim 63, wherein the polypeptide having an immunostimulatory activity is interleukin-2.

*I<sup>9</sup>  
cancel*

69. (Amended) The pharmaceutical composition according to claim 63, wherein the polypeptide having an immunostimulatory activity is the co-adhesion molecule B7.1.

*I<sup>10</sup>*

71. (Amended) The pharmaceutical composition according to claim 63, wherein said composition comprises:

- (a) a nononcogenic variant of an E6 region of a human papillomavirus, wherein said nononcogenic variant is a variant of the native E6 protein having amino acids 111-115 deleted as compared to the native E6 protein; and
- (b) a nononcogenic variant of an E7 region of a human papillomavirus, wherein said nononcogenic variant is a variant of the native E7 protein having amino acids 21-26 deleted as compared to the native E7 protein; and
- (c) interleukin 2.

*I<sup>11</sup>*

74. (Amended) The pharmaceutical composition of claim 63, wherein the papillomavirus is selected from the group consisting of HPV-16, HPV-18, HPV-31, HPV-33 and HPV-45 types.